NIH Guidelines April 2019

Esmeralda L Meyer1, Chris Jenkins2, Kalpana Rengarajan1

  • 1Emory University, Environmental Health and Safety Office, Atlanta, GA, USA.

Insights

The National Institutes of Health (NIH) updated its Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) in April 2019, focusing on human gene transfer studies and renaming the Recombinant DNA Advisory Committee (RAC) to NeXTRAC.

Area of Science:

  • Biotechnology
  • Genetics
  • Public Health Policy

Background:

  • The National Institutes of Health (NIH) periodically reviews and updates guidelines for scientific research.
  • Previous guidelines governed research involving recombinant or synthetic nucleic acid molecules.
  • Human gene transfer research has unique ethical and safety considerations.

Purpose of the Study:

  • To summarize the key changes in the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules published in April 2019.
  • To highlight the specific amendments pertaining to human gene transfer studies.
  • To announce the renaming of the Recombinant DNA Advisory Committee (RAC) and its new role.

Main Methods:

  • Review of the final amended NIH Guidelines published in April 2019.
  • Analysis of the changes related to human gene transfer research.
  • Identification of the rebranding of the RAC to NeXTRAC.

Main Results:

  • Final amendments to the NIH Guidelines were published in April 2019.
  • The updated guidelines emphasize review, registration, and reporting for human gene transfer studies.
  • The Recombinant DNA Advisory Committee (RAC) was renamed the Novel and Exceptional Technology and Research Advisory Committee (NeXTRAC).

Conclusions:

  • The updated NIH Guidelines aim to enhance oversight of human gene transfer research.
  • The establishment of NeXTRAC signifies a broader advisory scope for emerging biotechnologies.
  • These changes reflect the evolving landscape of genetic research and its regulation.

Related Concept Videos

Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
17
Standards of Care II01:19

Standards of Care II

Nurses bear specific legal responsibilities under several federal statutes, including:
722
Standards of Care I01:22

Standards of Care I

Federal statutes profoundly impact nursing practice, providing critical guidelines to ensure patient care is equitable, accessible, and of the highest quality. The following laws address distinct aspects of healthcare provision and patient rights:
757
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
672
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
26